Cargando…

PKPD modeling of acquired resistance to anti-cancer drug treatment

Non-small cell lung cancer (NSCLC) patients greatly benefit from the treatment with tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR). However, emergence of acquired resistance inevitable occurs after long-term treatment in most patients and limits clinical impr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eigenmann, Miro J., Frances, Nicolas, Lavé, Thierry, Walz, Antje-Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686279/ https://www.ncbi.nlm.nih.gov/pubmed/29090407 http://dx.doi.org/10.1007/s10928-017-9553-x

Ejemplares similares

gPKPDSim: a SimBiology(®)-based GUI application for PKPD modeling in drug development
por: Hosseini, Iraj, et al.
Publicado: (2018)

PKPD Modeling of the Inoculum Effect of Acinetobacter baumannii on Polymyxin B in vivo
por: Chauzy, Alexia, et al.
Publicado: (2022)

Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis
por: Gastine, Silke, et al.
Publicado: (2021)

Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
por: Mould, DR, et al.
Publicado: (2015)

Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD
por: Morse, James Denzil, et al.
Publicado: (2023)

PhysiPKPD: A pharmacokinetics and pharmacodynamics module for PhysiCell
por: Bergman, Daniel, et al.
Publicado: (2022)

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST
por: Hansson, E K, et al.
Publicado: (2013)

A Minimal PKPD Interaction Model for Evaluating Synergy Effects of Combined NSCLC Therapies
por: Ionescu, Clara Mihaela, et al.
Publicado: (2020)

Recent developments in using mechanistic cardiac modelling for drug safety evaluation
por: Davies, Mark R., et al.
Publicado: (2016)

Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling
por: Deroche, Luc, et al.
Publicado: (2023)

Fractional transit compartment model for describing drug delayed response to tumors using Mittag-Leffler distribution on age-structured PKPD model
por: Byun, Jong Hyuk, et al.
Publicado: (2022)

3552 Advancing Glioblastoma (GBM) drug regimen development to support combination therapy through integrated PKPD modeling and simulation-based predictions
por: Adhikari, Saugat, et al.
Publicado: (2019)

An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions
por: Guzzetti, Sofia, et al.
Publicado: (2023)

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized
por: Gautier, A, et al.
Publicado: (2013)

An improved PKPD modeling approach to characterize the pharmacodynamic interaction over time between ceftazidime/avibactam and colistin from in vitro time-kill experiments against multidrug-resistant Klebsiella pneumoniae isolates
por: Aubry, Romain, et al.
Publicado: (2023)

Subconjunctival Delivery of Sorafenib-Tosylate-Loaded Cubosomes for Facilitated Diabetic Retinopathy Treatment: Formulation Development, Evaluation, Pharmacokinetic and Pharmacodynamic (PKPD) Studies
por: Madhusudhan, Sharadha, et al.
Publicado: (2023)

A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis
por: Van De Vyver, Arthur, et al.
Publicado: (2021)

Combining an in silico proarrhythmic risk assay with a tPKPD model to predict QTc interval prolongation in the anesthetized guinea pig assay
por: Morissette, Pierre, et al.
Publicado: (2020)

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
por: Hansson, E K, et al.
Publicado: (2013)

Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper
por: Ménochet, Karelle, et al.
Publicado: (2022)

Imaging the Urokinase Plasminongen Activator Receptor in Preclinical Breast Cancer Models of Acquired Drug Resistance
por: LeBeau, Aaron M., et al.
Publicado: (2014)

Population pharmacokinetics and pharmacodynamics of investigational regimens’ drugs in the TB-PRACTECAL clinical trial (the PRACTECAL-PKPD study): a prospective nested study protocol in a randomised controlled trial
por: Nyang'wa, Bern-Thomas, et al.
Publicado: (2021)

Predicting treatment response to vancomycin using bacterial DNA load as a pharmacodynamic marker in premature and very low birth weight neonates: A population PKPD study
por: Samb, Amadou, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid
por: Eigenmann, Miro Julian, et al.
Publicado: (2021)

Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D(2) receptor antagonists risperidone, paliperidone and remoxipride in rats
por: Taneja, Amit, et al.
Publicado: (2016)

Acquired Resistance to Antituberculosis Drugs
por: Aung, Htin Lin, et al.
Publicado: (2018)

Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
por: Innao, Vanessa, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial
por: Olupot-Olupot, Peter, et al.
Publicado: (2023)

Drug-adapted cancer cell lines as preclinical models of acquired resistance
por: Michaelis, Martin, et al.
Publicado: (2019)

Nationwide Estimates of Viral Load Suppression and Acquired HIV Drug Resistance in Cameroon
por: Tchouwa, Gaëlle F., et al.
Publicado: (2018)

Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody
por: Wang, Chao, et al.
Publicado: (2017)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer
por: Kimura, Mariko, et al.
Publicado: (2018)

Yeasts Acquire Resistance Secondary to Antifungal Drug Treatment by Adaptive Mutagenesis
por: Quinto-Alemany, David, et al.
Publicado: (2012)

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
por: Uribe, Mary Luz, et al.
Publicado: (2021)

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review
por: Mallick, Jahan Saeed, et al.
Publicado: (2022)

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
por: Shah, Shalin, et al.
Publicado: (2017)

Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer
por: Li, Guangda, et al.
Publicado: (2021)

Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer
por: Bouhaddou, Mehdi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_slsb5mrbnm18rat2vobakcidcj